<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Pulmonary vein (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>) isolation (PVI) has emerged as an effective therapy for <z:hpo ids='HP_0004757'>paroxysmal atrial fibrillation</z:hpo> (AF) </plain></SENT>
<SENT sid="1" pm="."><plain>However, AF recurs in up to 50% of patients, generally because of recovery of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> conduction </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="3" ids="16335">Adenosine</z:chebi> given during the initial procedure may reveal dormant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> conduction, thereby identifying the need for additional ablation, leading to improved outcomes </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="3" ids="16335">Adenosine</z:chebi> Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination (ADVICE) study is a prospective multicentre randomized trial assessing the impact of <z:chebi fb="3" ids="16335">adenosine</z:chebi>-guided PVI in preventing AF recurrences </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Patients undergoing a first PVI procedure for paroxysmal AF will be recruited </plain></SENT>
<SENT sid="5" pm="."><plain>After standard PVI is completed, <z:hpo ids='HP_0000001'>all</z:hpo> patients will receive intravenous <z:chebi fb="3" ids="16335">adenosine</z:chebi> in an attempt to unmask dormant conduction </plain></SENT>
<SENT sid="6" pm="."><plain>If dormant conduction is elicited, patients will be randomized to no further ablation (control group) or additional <z:chebi fb="3" ids="16335">adenosine</z:chebi>-guided ablation until dormant conduction is abolished </plain></SENT>
<SENT sid="7" pm="."><plain>If no dormant conduction is revealed, randomly selected patients will be followed in a registry </plain></SENT>
<SENT sid="8" pm="."><plain>The primary outcome is time to first documented symptomatic AF recurrence </plain></SENT>
<SENT sid="9" pm="."><plain>Assuming that dormant conduction is present in 50% of patients post PVI and symptomatic AF recurs in 45% of controls, 244 patients with dormant conduction will be required to obtain &gt; 90% power to detect a difference of 20% </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, a total of 488 patients will be enrolled and followed for 12 months </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: The ADVICE trial will assess whether a PVI strategy incorporating elimination of dormant conduction unmasked by intravenous <z:chebi fb="3" ids="16335">adenosine</z:chebi> will decrease the rate of recurrent symptomatic AF compared with standard PVI </plain></SENT>
</text></document>